Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 0.04
NAS:BIOS's Cash-to-Debt is ranked lower than
77% of the 274 Companies
in the Global Medical Care industry.

( Industry Median: 0.28 vs. NAS:BIOS: 0.04 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:BIOS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 0.36 Max: No Debt
Current: 0.04
0
No Debt
Equity-to-Asset -0.06
NAS:BIOS's Equity-to-Asset is ranked lower than
96% of the 269 Companies
in the Global Medical Care industry.

( Industry Median: 0.48 vs. NAS:BIOS: -0.06 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:BIOS' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.18  Med: 0.4 Max: 0.75
Current: -0.06
-0.18
0.75
Debt-to-Equity -13.73
NAS:BIOS's Debt-to-Equity is ranked lower than
99.99% of the 202 Companies
in the Global Medical Care industry.

( Industry Median: 0.64 vs. NAS:BIOS: -13.73 )
Ranked among companies with meaningful Debt-to-Equity only.
NAS:BIOS' s Debt-to-Equity Range Over the Past 10 Years
Min: -179.79  Med: 0.13 Max: 332.35
Current: -13.73
-179.79
332.35
Debt-to-EBITDA 13.33
NAS:BIOS's Debt-to-EBITDA is ranked lower than
99% of the 201 Companies
in the Global Medical Care industry.

( Industry Median: 2.81 vs. NAS:BIOS: 13.33 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NAS:BIOS' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -17.97  Med: 9.98 Max: 38.87
Current: 13.33
-17.97
38.87
Interest Coverage 0.46
NAS:BIOS's Interest Coverage is ranked lower than
99% of the 227 Companies
in the Global Medical Care industry.

( Industry Median: 6.85 vs. NAS:BIOS: 0.46 )
Ranked among companies with meaningful Interest Coverage only.
NAS:BIOS' s Interest Coverage Range Over the Past 10 Years
Min: 0.35  Med: 0.77 Max: 8.98
Current: 0.46
0.35
8.98
Piotroski F-Score: 3
Altman Z-Score: 0.13
Beneish M-Score: -2.41
WACC vs ROIC
6.91%
5.12%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % 3.64
NAS:BIOS's Operating Margin % is ranked lower than
76% of the 272 Companies
in the Global Medical Care industry.

( Industry Median: 6.83 vs. NAS:BIOS: 3.64 )
Ranked among companies with meaningful Operating Margin % only.
NAS:BIOS' s Operating Margin % Range Over the Past 10 Years
Min: 0.74  Med: 2.83 Max: 6.03
Current: 3.64
0.74
6.03
Net Margin % -5.41
NAS:BIOS's Net Margin % is ranked lower than
85% of the 272 Companies
in the Global Medical Care industry.

( Industry Median: 3.88 vs. NAS:BIOS: -5.41 )
Ranked among companies with meaningful Net Margin % only.
NAS:BIOS' s Net Margin % Range Over the Past 10 Years
Min: -30.56  Med: -6.57 Max: 10.9
Current: -5.41
-30.56
10.9
ROA % -6.54
NAS:BIOS's ROA % is ranked lower than
89% of the 273 Companies
in the Global Medical Care industry.

( Industry Median: 3.48 vs. NAS:BIOS: -6.54 )
Ranked among companies with meaningful ROA % only.
NAS:BIOS' s ROA % Range Over the Past 10 Years
Min: -44.29  Med: -9.73 Max: 20.26
Current: -6.54
-44.29
20.26
ROC (Joel Greenblatt) % 16.18
NAS:BIOS's ROC (Joel Greenblatt) % is ranked lower than
87% of the 272 Companies
in the Global Medical Care industry.

( Industry Median: 14.91 vs. NAS:BIOS: 16.18 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:BIOS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -415.07  Med: 4.3 Max: 114.16
Current: 16.18
-415.07
114.16
3-Year Revenue Growth Rate -21.20
NAS:BIOS's 3-Year Revenue Growth Rate is ranked lower than
80% of the 211 Companies
in the Global Medical Care industry.

( Industry Median: 6.50 vs. NAS:BIOS: -21.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:BIOS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -35  Med: 3.9 Max: 15.9
Current: -21.2
-35
15.9
3-Year EBITDA Growth Rate -41.90
NAS:BIOS's 3-Year EBITDA Growth Rate is ranked lower than
99.99% of the 184 Companies
in the Global Medical Care industry.

( Industry Median: 5.90 vs. NAS:BIOS: -41.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:BIOS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -41.9 Max: 70.9
Current: -41.9
0
70.9
3-Year EPS without NRI Growth Rate 35.40
NAS:BIOS's 3-Year EPS without NRI Growth Rate is ranked higher than
73% of the 162 Companies
in the Global Medical Care industry.

( Industry Median: 8.40 vs. NAS:BIOS: 35.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:BIOS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -40.2 Max: 82.7
Current: 35.4
0
82.7
GuruFocus has detected 7 Warning Signs with BioScrip Inc NAS:BIOS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:BIOS's 30-Y Financials

Financials (Next Earnings Date: 2019-03-02 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2017

BIOS Guru Trades in Q4 2017

Joel Greenblatt 39,028 sh (New)
Chuck Royce 1,824,500 sh (+942.57%)
Paul Tudor Jones 75,549 sh (+32.42%)
Diamond Hill Capital 3,952,273 sh (+3.98%)
Mario Gabelli 815,074 sh (+0.27%)
Pioneer Investments 280,320 sh (unchged)
» More
Q1 2018

BIOS Guru Trades in Q1 2018

Chuck Royce 1,995,000 sh (+9.35%)
Paul Tudor Jones 117,305 sh (+55.27%)
Diamond Hill Capital 4,032,415 sh (+2.03%)
Mario Gabelli 847,574 sh (+3.99%)
Pioneer Investments 280,320 sh (unchged)
Joel Greenblatt 36,762 sh (-5.81%)
» More
Q2 2018

BIOS Guru Trades in Q2 2018

Chuck Royce 2,127,000 sh (+6.62%)
Pioneer Investments 280,320 sh (unchged)
Joel Greenblatt 30,181 sh (-17.90%)
Paul Tudor Jones 44,276 sh (-62.26%)
Diamond Hill Capital 4,017,981 sh (-0.36%)
Mario Gabelli 777,974 sh (-8.21%)
» More
Q3 2018

BIOS Guru Trades in Q3 2018

Chuck Royce 2,204,000 sh (+3.62%)
Pioneer Investments 280,320 sh (unchged)
Joel Greenblatt Sold Out
Mario Gabelli 680,324 sh (-12.55%)
Diamond Hill Capital 3,946,267 sh (-1.78%)
Paul Tudor Jones 24,934 sh (-43.69%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:BIOS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Health Care Providers » Medical Care    NAICS: 621610    SIC: 8082
Compare:TSX:DR, XKLS:0101, ASX:VRT, XTER:MED, ATH:HYGEIA, BOM:540797, HKSE:03869, OHEL:PIHLIS, SGX:QC7, NSE:MAXINDIA, HKSE:02389, HKSE:02120, HKSE:00286, NSE:HCG, TSE:2372, HKSE:01526, SGX:588, BKK:NTV, NYSE:AAC, XTER:M12 » details
Traded in other countries:MM6.Germany,
Headquarter Location:USA
BioScrip Inc provides home infusion & other home healthcare services to patients, physicians, hospitals, healthcare payors & pharmaceutical manufacturers to provide clinical management solutions & delivers cost-effective access to medications.

BioScrip Inc is one of the largest providers of home infusion services and home care management solutions in the United States. The firm's home infusion services primarily involve the intravenous administration of medications treating a wide range of acute and chronic conditions, such as infections, nutritional deficiencies, various immunologic and neurologic disorders, cancer, pain and palliative care. It provides a wide array of home infusion products and services to meet the diverse needs of physicians, patients, and payors. Its other services include anti-infective therapy, cardiac care, nutrition support, immunoglobulin therapy, hemophilia care, and respiratory/HME.

Ratios

vs
industry
vs
history
PS Ratio 0.70
BIOS's PS Ratio is ranked higher than
90% of the 262 Companies
in the Global Medical Care industry.

( Industry Median: 1.70 vs. BIOS: 0.70 )
Ranked among companies with meaningful PS Ratio only.
BIOS' s PS Ratio Range Over the Past 10 Years
Min: 0.04  Med: 0.37 Max: 1.89
Current: 0.7
0.04
1.89
EV-to-EBIT 86.25
BIOS's EV-to-EBIT is ranked lower than
99.99% of the 214 Companies
in the Global Medical Care industry.

( Industry Median: 21.68 vs. BIOS: 86.25 )
Ranked among companies with meaningful EV-to-EBIT only.
BIOS' s EV-to-EBIT Range Over the Past 10 Years
Min: -322.9  Med: 18.65 Max: 355.5
Current: 86.25
-322.9
355.5
EV-to-EBITDA 28.51
BIOS's EV-to-EBITDA is ranked lower than
91% of the 228 Companies
in the Global Medical Care industry.

( Industry Median: 15.23 vs. BIOS: 28.51 )
Ranked among companies with meaningful EV-to-EBITDA only.
BIOS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -342.3  Med: 16.45 Max: 113.8
Current: 28.51
-342.3
113.8
EV-to-Revenue 1.51
BIOS's EV-to-Revenue is ranked higher than
83% of the 271 Companies
in the Global Medical Care industry.

( Industry Median: 2.17 vs. BIOS: 1.51 )
Ranked among companies with meaningful EV-to-Revenue only.
BIOS' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.1  Med: 0.9 Max: 3
Current: 1.51
0.1
3
Current Ratio 1.79
BIOS's Current Ratio is ranked higher than
69% of the 260 Companies
in the Global Medical Care industry.

( Industry Median: 1.34 vs. BIOS: 1.79 )
Ranked among companies with meaningful Current Ratio only.
BIOS' s Current Ratio Range Over the Past 10 Years
Min: 0.86  Med: 1.36 Max: 2.76
Current: 1.79
0.86
2.76
Quick Ratio 1.55
BIOS's Quick Ratio is ranked higher than
64% of the 260 Companies
in the Global Medical Care industry.

( Industry Median: 1.24 vs. BIOS: 1.55 )
Ranked among companies with meaningful Quick Ratio only.
BIOS' s Quick Ratio Range Over the Past 10 Years
Min: 0.79  Med: 1.18 Max: 2.5
Current: 1.55
0.79
2.5
Days Inventory 24.89
BIOS's Days Inventory is ranked lower than
53% of the 206 Companies
in the Global Medical Care industry.

( Industry Median: 17.07 vs. BIOS: 24.89 )
Ranked among companies with meaningful Days Inventory only.
BIOS' s Days Inventory Range Over the Past 10 Years
Min: 11.42  Med: 22.67 Max: 80.5
Current: 24.89
11.42
80.5
Days Sales Outstanding 58.59
BIOS's Days Sales Outstanding is ranked higher than
54% of the 227 Companies
in the Global Medical Care industry.

( Industry Median: 39.87 vs. BIOS: 58.59 )
Ranked among companies with meaningful Days Sales Outstanding only.
BIOS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 36.18  Med: 71.16 Max: 178.08
Current: 58.59
36.18
178.08
Days Payable 51.06
BIOS's Days Payable is ranked lower than
64% of the 176 Companies
in the Global Medical Care industry.

( Industry Median: 40.58 vs. BIOS: 51.06 )
Ranked among companies with meaningful Days Payable only.
BIOS' s Days Payable Range Over the Past 10 Years
Min: 22.29  Med: 39.43 Max: 109.18
Current: 51.06
22.29
109.18

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -23.00
BIOS's 3-Year Average Share Buyback Ratio is ranked lower than
86% of the 159 Companies
in the Global Medical Care industry.

( Industry Median: -2.50 vs. BIOS: -23.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BIOS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -23  Med: -12.3 Max: -0.5
Current: -23
-23
-0.5

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 1.89
BIOS's Price-to-Median-PS-Value is ranked lower than
72% of the 208 Companies
in the Global Medical Care industry.

( Industry Median: 1.03 vs. BIOS: 1.89 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BIOS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.14  Med: 0.65 Max: 4.14
Current: 1.89
0.14
4.14
Earnings Yield (Greenblatt) % 1.16
BIOS's Earnings Yield (Greenblatt) % is ranked lower than
80% of the 273 Companies
in the Global Medical Care industry.

( Industry Median: 3.61 vs. BIOS: 1.16 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BIOS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -84.9  Med: 0.8 Max: 9.6
Current: 1.16
-84.9
9.6
Forward Rate of Return (Yacktman) % -20.29
BIOS's Forward Rate of Return (Yacktman) % is ranked lower than
89% of the 133 Companies
in the Global Medical Care industry.

( Industry Median: 9.10 vs. BIOS: -20.29 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
BIOS' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -16.4  Med: -2.1 Max: 0.3
Current: -20.29
-16.4
0.3

More Statistics

Revenue (TTM) (Mil) $707.92
EPS (TTM) $ -0.38
Beta0.01
Volatility60.48%
52-Week Range $2.31 - 4.13
Shares Outstanding (Mil)128.04

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 711 760 824
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) -0.39 -0.25 -0.12
EPS without NRI ($) -0.39 -0.25 -0.12
EPS Growth Rate
(Future 3Y To 5Y Estimate)
12.00%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAN
Positive CFROAN
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}